Tasso 80 mg Tablet is a targeted anticancer medication used in the management of specific types of advanced lung cancer. It is formulated for patients with metastatic non-small cell lung cancer (NSCLC) who carry a confirmed epidermal growth factor receptor (EGFR) T790M mutation and whose disease has progressed following prior EGFR tyrosine kinase inhibitor (TKI) therapy. This mutation must be identified using an FDA-approved diagnostic test before initiating treatment.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Cytotoxic Chemotherapy

Indications

Tasso 80 mg is indicated for the treatment of adult patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) whose disease has progressed on or after EGFR-TKI therapy.

Pharmacology and Mechanism of Action

Tasso 80 mg contains a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It selectively and irreversibly binds to mutant forms of EGFR, including T790M, L858R, and exon 19 deletion mutations, which are commonly associated with resistance to first-line EGFR-TKIs.
The T790M mutation increases ATP binding to EGFR, leading to reduced effectiveness of earlier therapies and poorer clinical outcomes. Tasso 80 mg specifically targets this gatekeeper mutation while sparing wild-type EGFR, thereby minimizing non-specific binding and reducing treatment-related toxicity.

Dosage and Administration

• The recommended dose of Tasso 80 mg is 80 mg taken orally once daily.

• Treatment should continue until disease progression or unacceptable toxicity occurs.

• The tablet may be taken with or without food.

• If a dose is missed, it should not be replaced; the next scheduled dose should be taken as usual.

Administration for Patients with Swallowing Difficulties

• Disperse the tablet in 60 ml of non-carbonated water, stir until broken into small pieces, and consume immediately.

• Do not crush, heat, or ultrasonicate the tablet.

• Rinse the container with 120–240 ml of water and drink immediately.

• For nasogastric tube administration, disperse the tablet in 15 ml water, transfer residue with an additional 15 ml water, and administer with appropriate tube flushing.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Drug Interactions

• Strong CYP3A4 Inducers: If coadministration is unavoidable, the dose of Tasso 80 mg should be increased to 160 mg daily.

• After discontinuation of the CYP3A4 inducer, resume the standard 80 mg dose after 3 weeks.

Side Effects

Commonly reported adverse effects include:

• Interstitial lung disease or pneumonitis

• QTc interval prolongation

• Cardiomyopathy

• Keratitis

Patients should be closely monitored for cardiac and pulmonary symptoms during therapy.

Pregnancy, Lactation, and Fertility

• Pregnancy: Tasso 80 mg is not recommended during pregnancy due to potential fetal harm observed in animal studies. Effective contraception is advised for women of childbearing potential.

• Lactation: Breastfeeding should be discontinued during treatment, as a risk to the infant cannot be excluded.

• Fertility: Animal studies indicate potential impairment of male and female fertility.

Storage Conditions

Store at room temperature between 20°C and 25°C. Keep out of reach of children. Dispose of unused or expired tablets safely.